Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Patient affordability does not justify compounding when FDA-approved alternatives exist
Adv Ther 3:2000029 Li B, Yao X, Li J, Lu X, Zhang W, Duan W et al (2023) A tumor microenvironment-activated metal-organic frameworkbased nanoplatform for amplified oxidative stressinduced enhanced chemotherapy
However, using an on-treatment exposure definition that followed patients while they were continuously exposed to the study drugs likely mitigated this bias
When comparing patients who initiated treatment with exenatide (n=14,076, median follow-up: 969 days), to those starting dulaglutide (n=54,787, median follow-up: 948 days) or liraglutide (n=25,562, median follow-up: 1,007 days), no differences were found in the hazard of composite treatment for diabetic macular edema (DME) and/or proliferative DR: exenatide vs
2012;7:e48872
Brain Res 552(2):346350
US$ 27.34
US$ 29.84
US$ 20.64
US$ 22.32
US$ 21.86
US$ 21.38
US$ 21.76
US$ 22.17
US$ 22.57
